[go: up one dir, main page]

EA200600356A1 - Комбинированная терапия для гликемического контроля - Google Patents

Комбинированная терапия для гликемического контроля

Info

Publication number
EA200600356A1
EA200600356A1 EA200600356A EA200600356A EA200600356A1 EA 200600356 A1 EA200600356 A1 EA 200600356A1 EA 200600356 A EA200600356 A EA 200600356A EA 200600356 A EA200600356 A EA 200600356A EA 200600356 A1 EA200600356 A1 EA 200600356A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glycemic control
combined therapy
diabetes mellitus
diabetes
niddm
Prior art date
Application number
EA200600356A
Other languages
English (en)
Inventor
Ханс-Ульрих Демут
Конрад Глунд
Маттиас Хоффманн
Original Assignee
Прозидион Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Прозидион Лимитед filed Critical Прозидион Лимитед
Publication of EA200600356A1 publication Critical patent/EA200600356A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Настоящее изобретение относится к способу лечения, в частности к способу лечения сахарного диабета, особенно инсулиннезависимого сахарного диабета (NIDDM) или диабета 2 типа, и состояний, ассоциированных с сахарным диабетом, преддиабетическим состоянием и/или ожирением, а также к композициям для применения в таком способе.
EA200600356A 2003-09-02 2004-09-02 Комбинированная терапия для гликемического контроля EA200600356A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49953503P 2003-09-02 2003-09-02
PCT/IB2004/003082 WO2005020983A2 (en) 2003-09-02 2004-09-02 Combination therapy for glycaemic control

Publications (1)

Publication Number Publication Date
EA200600356A1 true EA200600356A1 (ru) 2006-08-25

Family

ID=34272835

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600356A EA200600356A1 (ru) 2003-09-02 2004-09-02 Комбинированная терапия для гликемического контроля

Country Status (14)

Country Link
US (1) US20060287251A1 (ru)
EP (1) EP1663200A2 (ru)
JP (1) JP2007504213A (ru)
KR (1) KR20060119927A (ru)
CN (1) CN1845731A (ru)
AU (1) AU2004267955A1 (ru)
BR (1) BRPI0413204A (ru)
CA (1) CA2536432A1 (ru)
EA (1) EA200600356A1 (ru)
IL (1) IL173844A0 (ru)
MX (1) MXPA06002127A (ru)
NO (1) NO20061085L (ru)
WO (1) WO2005020983A2 (ru)
ZA (1) ZA200601770B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526291D0 (en) * 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
GB0623892D0 (en) * 2006-11-29 2007-01-10 Medical Res Council Technology Assay
US20130053310A1 (en) * 2010-03-26 2013-02-28 Novo Nordisk A/S Novel glucagon analogues
MX359329B (es) * 2011-10-28 2018-09-25 Sanofi Aventis Deutschland Una combinación farmacéutica para usarse en el tratamiento de un paciente que padece diabetes tipo 2.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE29924609U1 (de) * 1999-05-28 2004-04-22 Probiodrug Ag Neue Effektoren von Dipeptidylpeptidase IV
JP2003520226A (ja) * 2000-01-21 2003-07-02 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
EA007434B1 (ru) * 2002-02-28 2006-10-27 Прозидион Лимитед Ингибиторы dpiv на основе глутаминила
EP1543023B1 (en) * 2002-09-18 2010-03-17 Prosidion Limited Secondary binding site of dipeptidyl peptidase iv (dp iv)

Also Published As

Publication number Publication date
ZA200601770B (en) 2007-07-25
IL173844A0 (en) 2006-07-05
WO2005020983A3 (en) 2005-07-28
CN1845731A (zh) 2006-10-11
JP2007504213A (ja) 2007-03-01
US20060287251A1 (en) 2006-12-21
NO20061085L (no) 2006-05-31
KR20060119927A (ko) 2006-11-24
CA2536432A1 (en) 2005-03-10
BRPI0413204A (pt) 2006-10-03
EP1663200A2 (en) 2006-06-07
AU2004267955A1 (en) 2005-03-10
WO2005020983A2 (en) 2005-03-10
MXPA06002127A (es) 2006-05-31

Similar Documents

Publication Publication Date Title
TW200502385A (en) Modulation of forkhead box o1a expression
DE602004009295D1 (de) 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
ATE441418T1 (de) Verwendung von treprostinil zur verbesserung der nierenfunktion
EA200600235A1 (ru) Трёхзамещённые производные арилов и гетероарилов в качестве модуляторов метаболизма и профилактика и лечение связанных с ними нарушений
MX2009005935A (es) Compuestos biciclicos y su uso como anti-diabeticos.
ATE462427T1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
WO2008016648A3 (en) Certain chemical entities, compositions and methods
PT1143955E (pt) Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete
MXPA05004621A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes.
NO20072136L (no) Substans som fremmer GH-sekresjon og anvendelse derav
WO2004058158A3 (en) Treatment of metastatic cancer with the b-subunit of shiga toxin
DE60316821D1 (de) Aminobenzothiazolverbindungen mit nos-hemmender wirkung
IL186356A0 (en) Method of treating of preventing type-2 diabetes
WO2005039626A3 (en) Use of hydroxylated amino acids for treating diabetes
EA200600356A1 (ru) Комбинированная терапия для гликемического контроля
WO2003101284A3 (en) Methods of diagnosing and treating diabetes and insulin resistance
WO2006017171A3 (en) Methods of diagnosing & treating obesity, diabetes and insulin resistance
DE602004018162D1 (de) hERG1-KANAL-ÖFFNER ZUR BEHANDLUNG VON HERZARRYTHMIEN
WO2003103606A3 (en) Methods and compositions for treating and diagnosing diabetes
WO2024229151A3 (en) Multimeric coronavirus binding molecules and uses thereof
EP2096120A3 (en) Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
DE60033569D1 (de) Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
WO2003102161A3 (en) Methods of diagnosing & treating diabetes and insulin resistance
BRPI0506793A (pt) métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5